Bausch + Lomb Licenses US Commercial Rights for Eton Pharmaceuticals’ EM-100 to Treat Ocular Itching

 Bausch + Lomb Licenses US Commercial Rights for Eton Pharmaceuticals’ EM-100 to Treat Ocular Itching

Bausch + Lomb Licenses US Commercial Rights for Eton Pharmaceuticals’ EM-100 to Treat Ocular Itching

Shots:

  • Bausch + Lomb (Bausch Health’s subsidiary) acquires US commercial rights from Eton Pharmaceuticals for its EM-100, has been evaluated in P-III study vs PBO in patients with ocular itching associated with allergic conjunctivitis, demonstrated no AEs and non-inferiority data
  • The focus of the agreement is to strengthen Bausch’s portfolio of ophthalmology with the expansion of Eton Pharmaceuticals’EM-100 sales
  • Eton Pharmaceuticals’ EM-100 is a novel OTC preservative-free formulated eye drop used to treat itchy eyes associated with allergies with awaited FDA approval

Click here to read full press release/ article | Ref: Bausch Health | Image: USA today

Shiwani Sharma

Shiwani Sharma was Senior Editor at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post